|
1
|
El-Serag HB and Rudolph KL: Hepatocellular
carcinoma: Epidemiology and molecular carcinogenesis.
Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Llovet JM, Burroughs A and Bruix J:
Hepatocellular carcinoma. Lancet. 362:1907–1917. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cheng CF, Lu IH, Tseng HW, Sun CY, Lin LT,
Kuo ZK, Pan IH and Ko CH: Antitumor Effect of Periplocin in
TRAIL-Resistant Human Hepatocellular Carcinoma Cells through
Downregulation of IAPs. Evid Based Complement Alternat Med.
2013:Article ID 958025. 2013.
|
|
4
|
Chiao PJ, Na R, Niu J, Sclabas GM, Dong Q
and Curley SA: Role of Rel/NF-kappaB transcription factors in
apoptosis of human hepatocellular carcinoma cells. Cancer.
95:1696–1705. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wiley SR, Schooley K, Smolak PJ, et al:
Identification and characterization of a new member of the TNF
family that induces apoptosis. Immunity. 3:673–682. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wajant H, Pfizenmaier K and Scheurich P:
TNF-related apoptosis inducing ligand (TRAIL) and its receptors in
tumor surveillance and cancer therapy. Apoptosis. 7:449–459. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Srivastava RK: TRAIL/Apo-2L: Mechanisms
and clinical applications in cancer. Neoplasia. 3:535–546. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Spierings DC, de Vries EG, Vellenga E, et
al: Tissue distribution of the death ligand TRAIL and its
receptors. J Histochem Cytochem. 52:821–831. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Smyth MJ, Takeda K, Hayakawa Y, et al:
Nature's TRAIL - on a path to cancer immunotherapy. Immunity.
18:1–6. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Omar HA, Arafa SA, Maghrabi IA and Weng
JR: Sensitization of hepatocellular carcinoma cells to Apo2L/TRAIL
by a novel Akt/NF-κB signalling inhibitor. Basic Clin Pharmacol
Toxicol. 114:464–471. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang JS, Herreros-Villanueva M, Koenig A,
et al: Differential activity of GSK-3 isoforms regulates NF-κB and
TRAIL- or TNFα induced apoptosis in pancreatic cancer cells. Cell
Death Dis. 5:e11422014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Forde JE and Dale TC: Glycogen synthase
kinase 3: A key regulator of cellular fate. Cell Mol Life Sci.
64:1930–1944. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Song L, De Sarno P and Jope RS: Central
role of glycogen synthase kinase-3beta in endoplasmic reticulum
stress-induced caspase-3 activation. J Biol Chem. 277:44701–44708.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pak C and Miyamoto S: A new alpha in line
between KRAS and NF-κB activation? Cancer Discov. 3:613–615. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yao HB, Shaw PC, Wong CC and Wan DCC:
Expression of glycogen synthase kinase-3 isoforms in mouse
tissuesand their transcription in the brain. J Chem Neuroanat.
23:291–297. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Schwabe RF and Brenner DA: Role of
glycogen synthase kinase-3 in TNF-alpha-induced NF-kappaB
activation and apoptosis in hepatocytes. Am J Physiol Gastrointest
Liver Physiol. 283:G204–G211. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Coghlan MP, Culbert AA, Cross DA, et al:
Selective small molecule inhibitors of glycogen synthase kinase-3
modulate glycogen metabolism and gene transcription. Chem Biol.
7:793–803. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu J, Jiang G, Liu S, et al:
Lentivirus-delivered short hairpin RNA targeting SNAIL inhibits
HepG2 cell growth. Oncol Rep. 30:1483–1487. 2013.PubMed/NCBI
|
|
19
|
Kotliarova S, Pastorino S, Kovell LC,
Kotliarov Y, Song H, Zhang W, Bailey R, Maric D, Zenklusen JC, Lee
J, et al: Glycogen synthase kinase-3 inhibition induces glioma cell
death through c-MYC, nuclear factor-kappaB, and glucose regulation.
Cancer Res. 68:6643–6651. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kim SJ, Lim JY, Lee JN, Choe SK, Kim YI,
Song SR, Cho M, So HS and Park R: Activation of β-catenin by
inhibitors of glycogen synthase kinase-3 ameliorates
cisplatin-induced cytotoxicity and pro-inflammatory cytokine
expression in HEI-OC1 cells. Toxicology. 320:74–82. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang H, Sui A, Wang Z, Liu S and Yao R:
Adenovirus-mediated TRAIL expression and downregulation of Bcl-2
expression suppresses non-small cell lung cancer growth in vitro
and in vivo. Int J Mol Med. 30:358–364. 2012.PubMed/NCBI
|
|
22
|
Kim HS, Loughran PA, Rao J, Billiar TR and
Zuckerbraun BS: Carbon monoxide activates NF-kappaB via ROS
generation and Akt pathways to protect against cell death of
hepatocytes. Am J Physiol Gastrointest Liver Physiol.
295:G146–G152. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jope RS and Johnson GV: The glamour and
gloom of glycogen synthase kinase-3. Trends Biochem Sci. 29:95–102.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Beurel E and Jope RS: The paradoxical pro-
and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic
apoptosis signaling pathways. Prog Neurobiol. 79:173–189. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chen KF, Yeh PY, Hsu C, Hsu CH, Lu YS,
Hsieh HP, Chen PJ and Cheng AL: Bortezomib overcomes tumor necrosis
factor-related apoptosis-inducing ligand resistance in
hepatocellular carcinoma cells in part through the inhibition of
the phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem.
284:11121–11133. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Newsom-Davis T, Prieske S and Walczak H:
Is TRAIL the holy grail of cancer therapy? Apoptosis. 14:607–623.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Munshi A, Pappas G, Honda T, McDonnell TJ,
Younes A, Li Y and Meyn RE: TRAIL (APO-2L) induces apoptosis in
human prostate cancer cells that is inhibitable by Bcl-2. Oncogene.
20:3757–3765. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen X, Thakkar H, Tyan F, Gim S, Robinson
H, Lee C, Pandey SK, Nwokorie C, Onwudiwe N and Srivastava RK:
Constitutively active Akt is an important regulator of TRAIL
sensitivity in prostate cancer. Oncogene. 20:6073–6083. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Loberg RD, Vesely E and Brosius FC III:
Enhanced glycogen synthase kinase-3beta activity mediates
hypoxia-induced apoptosis of vascular smooth muscle cells and is
prevented by glucose transport and metabolism. J Biol Chem.
277:41667–41673. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Watcharasit P, Bijur GN, Zmijewski JW,
Song L, Zmijewska A, Chen X, Johnson GV and Jope RS: Direct,
activating interaction between glycogen synthase kinase-3beta and
p53 after DNA damage. Proc Natl Acad Sci USA. 99:7951–7955. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Klamer G, Song E, Ko KH, O'Brien TA and
Dolnikov A: Using small molecule GSK3β inhibitors to treat
inflammation. Curr Med Chem. 17:2873–2881. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Medina M and Avila J: Glycogen synthase
kinase-3 (GSK-3) inhibitors for the treatment of Alzheimer's
disease. Curr Pharm Des. 16:2790–2798. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Liao X, Zhang L, Thrasher JB, Du J and Li
B: Glycogen synthase kinase-3β suppression eliminates tumor
necrosis factor-related apoptosis-inducing ligand resistance in
prostate cancer. Mol Cancer Ther. 2:1215–1222. 2003.PubMed/NCBI
|
|
34
|
Huerta-Yepez S, Vega M, Jazirehi A, Garban
H, Hongo F, Cheng G and Bonavida B: Nitric oxide sensitizes
prostate carcinoma cell lines to TRAIL-mediated apoptosis via
inactivation of NF-kappa B and inhibition of Bcl-xl expression.
Oncogene. 23:4993–5003. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hoeflich KP: Requirement for glycogen
synthase kinase-3β cell survival and NF-κB activation. Nature.
406:86–90. 2001. View
Article : Google Scholar
|
|
36
|
Wilson W III and Baldwin AS: Maintenance
of constitutive IkappaB kinase activity by glycogen synthase
kinase-3alpha/beta in pancreatic cancer. Cancer Res. 68:8156–8163.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Deveraux QL and Reed JC: IAP family
proteins - suppressors of apoptosis. Genes Dev. 13:239–252. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sun M, Zhou T, Jonasch E and Jope RS: DDX3
regulates DNA damage-induced apoptosis and p53 stabilization.
Biochim Biophys Acta. 1833:1489–1497. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Carbone C and Melisi D: NF-kB as a target
for pancreatic cancer therapy. Expert Opin Ther Targets. 16:1–10.
2012. View Article : Google Scholar : PubMed/NCBI
|
